Optimal Value-Based Therapy

Ken Schaecher, MD

Video Categories: Polycythemia Vera

Listen as Ken Schaecher, MD discusses the optimal value-based therapy for treatment of polycythemia vera.

Supported through funding from Incyte
January 17, 2019

Identifying and Solving Top Challenges to Oncology Biomarker Testing

Drs. David Rimm and Roy Herbst identify the top challenges in the area of biomarker testing as well as solutions to these challenges, including availability of sufficient tissue for a large number of biomarker assays, the time some biomarker tests require for completion, the need for a tight association of [ Read More ]

September 2, 2015

Changing the Way Takeda Oncology Develops Cancer Medicines

Dixie-Lee Esseltine, MD and George Mulligan, PhD offer insight on the impact of ixazomib on Takeda Oncology’s approach to multiple myeloma care and its approach to other cancer types.